Health Care Select Sector SPDR Fund (XLV)
| Assets | $35.43B |
| Expense Ratio | 0.09% |
| PE Ratio | 28.28 |
| Shares Out | 257.92M |
| Dividend (ttm) | $2.34 |
| Dividend Yield | 1.70% |
| Ex-Dividend Date | Mar 24, 2025 |
| Payout Ratio | 47.70% |
| 1-Year Return | -1.04% |
| Volume | 4,315,290 |
| Open | 138.98 |
| Previous Close | 138.54 |
| Day's Range | 137.31 - 138.98 |
| 52-Week Low | 129.66 |
| 52-Week High | 159.64 |
| Beta | 0.71 |
| Holdings | 62 |
| Inception Date | Dec 16, 1998 |
About XLV
Fund Home PageThe Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund that is based on the S&P Health Care Select Sector index. The fund tracks health care stocks from within the S&P 500 Index, weighted by market cap. XLV was launched on Dec 16, 1998 and is issued by State Street.
Top 10 Holdings
57.10% of assets| Name | Symbol | Weight |
|---|---|---|
| Eli Lilly and Company | LLY | 11.77% |
| UnitedHealth Group Incorporated | UNH | 10.69% |
| Johnson & Johnson | JNJ | 7.36% |
| AbbVie Inc. | ABBV | 6.20% |
| Abbott Laboratories | ABT | 4.37% |
| Merck & Co., Inc. | MRK | 3.96% |
| Intuitive Surgical, Inc. | ISRG | 3.46% |
| Thermo Fisher Scientific Inc. | TMO | 3.40% |
| Amgen Inc. | AMGN | 3.13% |
| Boston Scientific Corporation | BSX | 2.75% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Mar 24, 2025 | $0.56454 | Mar 26, 2025 |
| Dec 23, 2024 | $0.62165 | Dec 26, 2024 |
| Sep 23, 2024 | $0.57723 | Sep 25, 2024 |
| Jun 24, 2024 | $0.57253 | Jun 26, 2024 |
| Mar 18, 2024 | $0.52294 | Mar 21, 2024 |
| Dec 18, 2023 | $0.59772 | Dec 21, 2023 |
News
Trump Says Pharmaceutical Tariffs Coming in Near Future
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporter...
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told...
Explainer: Prescription drugs become a target in Trump's trade war
U.S. President Donald Trump late on Tuesday reiterated he would impose tariffs on imports of pharmaceutical products that have long been spared from past trade disputes due to the potential for harm t...
Healthcare Stocks Aren't a Shelter From the Tariff Storm
It's increasingly clear that broad bets on healthcare don't make sense as a refuge from the market chaos.
Why drug stocks are no longer a safe haven from the stock market's turmoil
Shares of drugmakers were taking a broad beating Wednesday, after President Donald Trump indicated that pharmaceuticals will no longer be excluded from tariffs.
Mizuho's Jared Holz: Here's why healthcare stocks are under pressure
Jared Holz, Mizuho Securities America healthcare sector strategist, joins CNBC's 'Power Lunch' to discuss whether the healthcare sector is actually a safe haven during the market turmoil, why healthca...
XLV: My Method For Navigating These Pullbacks
The Health Care Select Sector SPDR® Fund ETF is a highly representative ETF with $38.42 billion in AUM, a competitive expense ratio of 0.09%, and a dividend yield of 1.48%. Despite a 7% price drop sin...
Final Trade: MO, HYG, XLV, XOM
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Energy And Healthcare Stocks Are Big Winners This Year
The Energy Select Sector SPDR ETF is up 8.0% so far this year, far ahead of the broad market, which is nursing a 3.5% year-to-date loss. Healthcare stocks are a strong runner-up performer, rising 6.6%...
Financials, Health Care & BRK/B: Investments to Tackle Volatility
Patrick Mueller notes the market's volatile swings seen through tariffs and policy uncertainty under the Trump administration. That doesn't mean there's no room for investors to enter the market.
Healthcare Stocks Avoid Tariff Damage. There Are Other Problems.
The threat of cuts to Medicaid, plus uncertainty over what the confirmation of Robert F. Kennedy Jr. to lead the U.S. health bureaucracy will mean for the sector, have weighed on the stocks.
Committee Stocks on the Move: Lowe's, TJX Companies, Eli Lilly and the XLV
The Investment Committee discuss some of their stocks that are moving today.
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US admini...
Undercovered ETFs: Growth, Income, TIPS, Poland +
The 'Undercovered' Dozen series highlights 12 lesser-known ETFs offering potential investment opportunities for investors. Kurtis Hemmerling shares a bearish take on iShares Russell Top 200 Growth ETF...
Final Trade: FWONK, XLV, MSFT, PEP
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
Five ETFs to invest in to hedge against policy uncertainty in 2025
As economic and political uncertainties mount, investors are shifting their strategies toward risk-off investments—assets that provide stability and resilience during volatile periods. With significan...
Financials, Health Care Sectors Leading U.S. Stocks Higher In 2025
The Financial Select Sector SPDR ETF is up 7.8% so far this year. Health care is a close second-place performer with a 6.9% year to date rise.
Healthcare and industrials are two underperforming sectors to watch, says Trivariate's Adam Parker
Trivariate's Adam Parker and Robinhood's Stephanie Guild, join 'Closing Bell' to discuss hyperscalers CapEx numbers and AI spending.
How tariffs could impact pharma and early-stage healthcare investments
Carl Rizzuto, Versant Ventures managing director, joins 'Fast Money' to talk the impact of tariffs on healthcare.
XLV: With Relative Strength In January And Compelling Valuation, Health Care Earnings On Tap
I maintain a buy rating on the Health Care sector, highlighting XLV as the second-best performing S&P 500 sector YTD with broad-based gains. Global fund managers have increased allocations to Health C...
XLV: Buy Diversity And Growth
XLV offers a rare combination of stability and growth potential through its diverse investments in the healthcare sector, justifying a buy rating. The fund's broad exposure across various healthcare s...
The Big 3: META, SLV, XLV
Meta Platforms (META) reports earnings after the closing bell, and @Theotrade's Don Kaufman is bearish on the Mag 7 company. He thinks Meta's significant run higher could end as Don expects its report...
Health care bounce is starting to brew, says Strategas' Chris Verrone
Chris Verrone, Strategas head of technical and macro research, joins 'Closing Bell' to discuss the bullish technical signs he's seeing.